The U.S. Food and Drug Administration (FDA) has granted an expanded indication for Merck & Co.’s 21-valent pneumococcal conjugate vaccine, Capvaxive (marketed as MSD outside the United States and Canada). Executed on June 18, 2026, the regulatory clearance authorizes the use of the vaccine in children and adolescents aged 2 through 17 years who have completed a primary pediatric pneumococcal vaccination series and present with one or more chronic medical comorbidities that increase their susceptibility to pneumococcal disease.
With this decision, Capvaxive establishes itself as the only Pneumococcal Conjugate Vaccine (PCV) specifically studied and indicated within the United States for this targeted pediatric sub-population.
The documented STRIDE-13 comparative trial baselines, strict medical contraindications, and the vaccine’s anniversary milestones feature:
-
High-Risk Target Stratification and Specialized Immunological Protection:
-
Eligibility Criteria: The updated pediatric label is strictly sequestered to patients aged 2–17 who have cleared their routine primary childhood pneumococcal series and are diagnosed with specific underlying chronic medical conditions. Dr. Rotem Lapidot, a STRIDE-13 investigator and Chief of Pediatric Infectious Diseases at Rambam Health Care Campus, noted that children presenting with certain chronic comorbidities face significantly elevated baseline risks for invasive pathologies, including pneumonia, meningitis, and severe bloodstream infections.
-
Supplemental Shielding: The expanded regulatory mandate recognizes Capvaxive’s capacity to deliver additional disease protection by incorporating specific bacterial serotypes that are entirely absent from legacy primary pediatric PCV series currently approved in the marketplace, representing a novel clinical approach to protecting vulnerable youth.
-
-
The Phase III STRIDE-13 Framework and Post-Marketing Verification Contingencies:
-
Active Comparison Trials: The FDA’s regulatory expansion was anchored by clinical readouts derived from the Phase III STRIDE-13 trial, a controlled clinical study evaluating the investigational Capvaxive formulation directly against the 23-valent pneumococcal polysaccharide vaccine, PPSV23.
-
Confirmatory Mandates: Federal regulators clarified that continued accelerated or expanded approval for this pediatric indication may be legally contingent upon the subsequent verification and description of verified clinical benefits within post-marketing confirmatory trials.
-
-
Dual-Year Anniversary Convergence and Regulatory Medical Contraindications:
-
Timeline Intersections: Notably, the official announcement of the expanded pediatric indication materialized exactly two years to the day since the FDA issued its historic initial approval of Capvaxive for adult populations (June 18, 2024). Dr. Paula Annunziato, Senior Vice President of Infectious Diseases and Vaccines, Global Clinical Development at Merck Research Laboratories, emphasized that while Capvaxive was fundamentally engineered to target adult epidemiological profiles, it offers a crucial added layer of disease protection for this specific high-risk subset of children when administered after their primary series.
-
Exclusion Parameters: The approved prescribing information mandates that individuals with established histories of severe allergic reactions (such as anaphylaxis) to any constituent component of Capvaxive, or to diphtheria toxoid platforms, must not receive the vaccine.
-